Search results
Results from the WOW.Com Content Network
NVAX data by YCharts. Novavax's late-stage trials hit a snag. Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on ...
Moderna cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine.The company now expects $1.5 to $2 billion in revenue ...
Kennedy has long railed against vaccines, once calling those that protect against Covid-19 a "crime against humanity." He has treaded more carefully in recent weeks, though, and has said he wouldn ...
Unlike the COVID-19 pandemic, when the U.S. government subsidized private companies to make the COVID-19 vaccine, the government actually has a stockpile of H5N1 virus candidates that could be ...
Trump said during a rally in late October that he would let Kennedy “go wild” on healthcare in the country, and vaccine stocks like Moderna and Novavax have been heading lower since. Thursday ...
After Moderna’s development of a COVID-19 vaccine fueled a massive surge in revenue — rising more than 2,000% in 2021 from the prior year, with the vaccine maker turning its first-ever profit ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
COVID-19 vaccines gave Moderna, Pfizer and Johnson & Johnson a boost — but are their stocks still good buys in 2021? Here's what to consider before investing.